Venture Opportunity Fund Atlas Purchases 17,857 Shares of Korro Bio, Inc. (NASDAQ:KRRO) Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Venture Opportunity Fund Atlas purchased 17,857 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were bought at an average price of $56.00 per share, with a total value of $999,992.00. Following the completion of the acquisition, the insider now owns 195,074 shares of the company’s stock, valued at approximately $10,924,144. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Korro Bio Stock Performance

NASDAQ:KRRO opened at $62.99 on Thursday. Korro Bio, Inc. has a 12 month low of $9.15 and a 12 month high of $97.91. The company has a market capitalization of $505.18 million, a price-to-earnings ratio of -0.67 and a beta of 2.18. The company has a 50 day moving average price of $64.40.

Hedge Funds Weigh In On Korro Bio

A number of institutional investors have recently modified their holdings of KRRO. Atlas Venture Life Science Advisors LLC bought a new position in shares of Korro Bio in the fourth quarter valued at approximately $53,648,000. Eventide Asset Management LLC bought a new position in shares of Korro Bio in the fourth quarter valued at approximately $26,185,000. 72 Investment Holdings LLC bought a new position in shares of Korro Bio in the fourth quarter valued at approximately $13,269,000. Monashee Investment Management LLC bought a new position in shares of Korro Bio in the fourth quarter valued at approximately $4,352,000. Finally, North Star Investment Management Corp. bought a new position in Korro Bio during the fourth quarter worth $48,000. Institutional investors own 13.18% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on KRRO shares. Piper Sandler restated an “overweight” rating and set a $180.00 price target on shares of Korro Bio in a report on Wednesday, March 27th. HC Wainwright raised their price target on shares of Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. BMO Capital Markets restated an “outperform” rating and set a $120.00 price target on shares of Korro Bio in a report on Tuesday, March 26th. Finally, Royal Bank of Canada lifted their target price on shares of Korro Bio from $70.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, March 27th.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.